Company intelligence / Profile preview
Monopar Therapeutics Inc.
Wilmette, Illinois, United Statesmonopartx.com ↗
- Ownership
- Public · MNPR
- Development stage
- Phase 3
01
Overview
Monopar has multiple clinical programs including ALXN1840 for Wilson Disease (Phase 3 complete), MNPR-101-Zr imaging agent (Phase 1 active and recruiting), MNPR-101-Lu therapeutic (Phase 1a active and recruiting), and MNPR-101-Ac (late preclinical). Recent clinical data shows promising tumor uptake of MNPR-101-Zr in advanced cancer patients.
- Therapeutic areas
- OncologyRare Diseases
- Modalities
- RadiopharmaceuticalsAntibodiesSmall molecules
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
03
Partnerships
NorthStar Medical RadioisotopesAlexion Pharmaceuticals (licensing agreement)
04
Financials
- Market cap
- $451.2M
- Total revenue
- $0
- Enterprise value
- $317M
Beyond the preview
Go deeper on Monopar Therapeutics Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Monopar Therapeutics Inc..